Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240423 | 0.96 | RAB9A (0.50) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL30402035 | 0.96 | RAB9A (0.50) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL10803637 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL13458070 | 0.86 | RAB9A (0.58) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL23731087 | 0.82 | CYP1A2 (0.64) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL256008 | 0.82 | HSD11B1 (0.48) | SMN1; SMN2NPC1RAB9ACYP1A2MEN1 | |
| SCHEMBL2493590 | 0.81 | RAB9A (0.62) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL23565886 | 0.79 | PTGS2 (0.50) | SMN1; SMN2NPC1RAB9AUSP2TP53 | |
| SCHEMBL3152568 | 0.78 | KDM4E (0.42) | SMN1; SMN2NPC1RAB9ATP53PKM | |
| SCHEMBL2314305 | 0.78 | MAPT (0.45) | SMN1; SMN2NPC1RAB9AUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168576-A2 | New utilities of tricyclic compounds | Shionogi & Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20080318958-A1 | New utilities of tricyclic compounds | ISHIZUKA NATSUKI | 2008-12-25 | — | — | US | disclosed |
| US-20080318958-A1 | New utilities of tricyclic compounds | ISHIZUKA NATSUKI | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318958-A1 | New utilities of tricyclic compounds | APOB, PON1, APOL1 | SMN1; SMN2 2752/4885NPC1 35/4885RAB9A 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.